PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4127-4157

  Poulin, Patrick ^a   Jones, Rhys D O ^b   Jones, Hannah M ^c   Gibson, Christopher R ^d   Rowland, Malcolm ^e   Chien, Jenny Y ^f   Ring, Barbara J ^f   Adkison, Kimberly K ^g   Ku, M Sherry ^h   He, Handan ⁱ   Vuppugalla, Ragini ^j   Marathe, Punit ^j   Fischer, Volker ^k   Dutta, Sandeep ^k   Sinha, Vikash K ^l   Björnsson, Thorir ^m   Lavé, Thierry ⁿ   Yates, James W T ^b  

^a AstraZeneca Ltd ^*  (Canada)

^b ASTRAZENECA   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f ELI LILLY AND COMPANY   (United States)

^g GLAXOSMITHKLINE   (United States)

^h Anchen Pharmaceuticals Inc   (United States)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k ABBOTT LABORATORIES   (United States)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m CRITICAL PATH INSTITUTE   (United States)

ⁿ F HOFFMANN LA ROCHE LTD   (Switzerland)

more..

Author keywords

Absorption; Animal alternative; Computational ADME; Disposition; Distribution; Drug development; Drug discovery; In vitro in vivo correlation; PBPK modeling; Pharmacokinetics

Indexed keywords

ADIPOSE DERIVED STEM CELL; AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BONE; BRAIN; DRUG CLEARANCE; DRUG DIFFUSION; DRUG SOLUBILITY; HEART; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; KIDNEY; LIPOPHILICITY; LIVER; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PREDICTIVE VALUE; SIMULATION; SKIN CULTURE; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; VENOUS BLOOD; ACCESS TO INFORMATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; COMPUTER SIMULATION; COOPERATION; DRUG DATABASE; DRUG DEVELOPMENT; DRUG SCREENING; EVALUATION STUDY; GASTROINTESTINAL ABSORPTION; INTERDISCIPLINARY COMMUNICATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; REPRODUCIBILITY; SPECIES DIFFERENCE; STATISTICAL MODEL;

DRUG;

ACCESS TO INFORMATION; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; COMPUTER SIMULATION; COOPERATIVE BEHAVIOR; DATABASES, PHARMACEUTICAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL ABSORPTION; HUMANS; INTERDISCIPLINARY COMMUNICATION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY;

EID: 80052262709     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22550     Document Type: Article

References (50)

1. Poulin P, Jones HM, Jones RDO, Yates JWT, Gibson R, Chien JY, Ring BJ, Adkison KK, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Ku MS. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 1. Goals, properties of the PhRMA dataset and comparison with literature datasets. J Pharm Sci 100 (submitted as a companion paper).
2. Jones RDO, Jones HM, Rowland M, Gibson CR, Yates JWT, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, Vuppugalla R, Marathe M, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 2. Comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 100 (submitted as a companion paper).
3. Ring B, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 3. Comparative assessment of prediction methods of human clearance. J Pharm Sci 100 (submitted as a companion paper).
4. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. 2009. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533.
5. Vuppugalla R, Marathe P, He H, Jones RDO, Yates JWT, Jones HM, Gibson CR, Chien JY, Ring BJ, Adkison KK, Ku MS, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 4. Prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100 (submitted as a companion paper).
6. Dedrick R, Bischoff KB, Zaharko DS. 1970. Interspecies correlation of plasma concentration history of methotrexate. Cancer Chemother Rep 54:95-101.
7. Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890-1900.
8. Krishnan K, Andersen ME. 2007. Physiologically-based pharmacokinetic modeling in toxicology. In Principles and methods of toxicology; Hayes, A.W., Ed. Boca Raton: Taylor & Francis, pp. 231-292.
9. Theil FP, Guentert TW, Haddad S, Poulin P. 2003. Utility of physiologically-based pharmacokinetic (PBPK) model to drug development and rational drug discovery candidate selection. Tox Lett 138:29-49.
10. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 Suppl 1:S41-67.
11. Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. 2003. Physiologically-based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 92:1990-2007.
12. Jones HM, Parrott N, Jorga K, Lave T. 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 45(5):511-542.
13. Jones HM, Gardner IB, Watson KJ. 2009. Modeling and PBPK simulation in drug discovery. AAPS J 11:155-166.
14. Jamei M, Marciniak F, Feng K, Barnett A, Tucker G, Rostami-Hogjegan A. 2009. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2:211-223.
15. Lavé T, Parrott N, Grimm HP, Fleury A, Reddy M. 2007. Challenges and opportunities with modeling and simulation in drug discovery and drug development. Xenobiotica 37:1295-1310.
16. Lowe PJ, Hijazi Y, Luttringer O, Yin H, Sarangapani R, Howard D. 2007. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37:1331-1354.
17. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. 2007. Prediction of human pharmacokinetics using physiologically based modeling: A retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780.
18. Huang C, Zheng M, Yang Z, Rodrigues AD, Marathe P. 2008. Projection of exposure and efficacious dose prior to first-in-human studies: How successful have we been? Pharm Res 25:713-726.
19. Peters SA. 2008. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 47:261-275.
20. Gabrielsson J, Dolgos H, Gillberg PG, Bredberg U, Benthem B, Duker G. 2009. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: Strategic considerations. Drug Discov Today 14:358-372.
21. Fenneteau F, Poulin P, Nekka F. 2009. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 99:486-514.
22. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
23. Berezhkovskiy LM. 2004. Volume of distribution at steady-state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
24. Rodgers T, Rowland M. 2007. Mechanistic approaches to volume of distribution predictions: Understanding the processes. Pharm Res 24:918-933.
25. Arundel PA. 1997. A multi-compartmental model generally applicable to physiologically-based pharmacokinetics. (Astra-Zeneca, UK). Poster presentation during the third IFAC symposium. Modeling and control in biomathematical systems. UK: University of Warwick, 23-26 March.
26. Jansson R, Bredberg U, Ashton M. 2008. Prediction of drug tissue to plasma concentration ratios using a measured volume of distribution in combination with lipophilicity. J Pharm Sci 97:2324-2339.
27. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. 1996. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 13:163-167.
28. Davies B and Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
29. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
30. Turner DB, Rostami-Hodjegan A, Tucker GT, Yeo KR. 2007. Prediction of non-specific hepatic microsomal binding from readily available physicochemical properties. Drug Metab Disp 38 (S1):162-163.
31. Tang H, Mayersohn M. 2005. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 33:1297-1303.
32. Lin L, Hedayat AS, Wu W. 2007. A unified approach for assessing agreement for continuous and categorical data. J Biopharm Stat 17:629-652.
33. Poulin P, Ekin S, Theil FP. 2011. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 250:194-212.
34. Keldenich J. 2009. Measurement and prediction of oral absorption: A review. Chem Biodivers 6:2000-2013.
35. Custodio JM, Wu CY, Benet LZ. 2008. Predicting drug disposition, transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 60:717-733.
36. Wong W, Theil FP, Cui Y, Khojasteh SC, Marsters JC, Vernillet L, La H, Song X, Wang H, Morinello E, Deng Y, Cornelis ECA Hop. 2010. Interlay of dissolution, solubility, and nonsink permeation determines the oral absorption of the hedgehog pathway inhibitor GDC-0449 in dogs: An investigation using preclinical studies and physiologically based pharmacokinetic model. Drug Met Disp 38:1029-1038.
37. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm Res 15:1792-1795.
38. Germani M, Crivori P, Rocchetti M, Burton PS, Wilson AGE, Smith ME, Poggesi I. 2007. Evaluation of a basic physiologically-based pharmacokinetic model for simulating the first time in animal study. Eur J Pharm Sci 31:190-201.
39. Allan G, Davis J, Dickins M, Gardner I, Jenkins T. 2008. Pre-clinical pharmacokinetics of UK-453, 061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453, 061 in man. Xenobiotica 38:620-640.
40. Gibson CR, Bergman A, Lu P, Kesisoglou F, Denney WS, Mulrooney E. 2009. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modeling. Xenobiotica 39:637-648.
41. Parrott N, Lavé T. 2008. Applications of physiologically based absorption models in drug discovery and development. Mol Pharmaceutics 5:760-775.
42. Parrott N, Lucakova V, Fraczkiewicz G, Bolger MB. 2009. Predicting pharmacokinetics of drugs using physiologically-based modeling-Application to food effects. AAPS 11:45-53.
43. Watanabe T, Kusuhara H, Sugiyama Y. 2010. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans. J Pharmacokin Pharmacodyn 37: 575-590.
44. Haddad S, Poulin P, Funk C. 2010. Extrpolating in vitro metabolic interactions to isolated perfused liver: Prediction of metabolic interactions between bufarolol, bunitrolol and debrisoquine. J Pharm Sci 99:4406-4426.
45. Rowland K Yeo, Jamei M, Yang J, Tucker GT, Rostami-Hodjegan A. 2010. Physiologically based mechanistic modeling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut-The effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci. 39:298-309.
46. Krishnan K, Haddad S, Béliveau M, Tardif R. 2002. Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures. Environ Health Perspect. Suppl 6:989-94.
47. Peyret T, Poulin P, Krishnan K. 2010. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 249:197-207.
48. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. 2009. The SIMCYP population-based ADME simulator. Expert Opin Drug Metab Toxicol. 5:211-23.
49. Rowland M, Peck C, Tucker G. 2011. Physiologically based pharmacokinetic in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51: 45-73.
50. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP, Rahman NA, Reynolds KS, Berglund EG, Lesko LG, Huang SM. 2011. Application of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther: 259-267.